Literature DB >> 26451964

Effectiveness of a risk-minimization activity involving physician education on metabolic monitoring of patients receiving quetiapine: results from two postauthorization safety studies.

Robert S Brody1, Charles L Liss, Heather Wray, Ramon Iovin, Carmen Michaylira, Anushini Muthutantri, Philip Damstetter, Catherine Datto, Leigh Jefferies.   

Abstract

Following Good Pharmacovigilance Practices Module XVI, two complementary studies were performed that included process and outcome measurements of the effectiveness of physician education on metabolic monitoring of patients receiving quetiapine. A multinational survey of 800 European Union physicians was utilized to assess the receipt of educational materials and also to assess the degree of monitoring as reported by physicians. Recall of receipt of educational materials ranged from 16.0 to 69.0% across the participating countries; however, physicians reported that 64.5% of patients were being monitored, with the majority reporting performance of three or more of four key metabolic-monitoring activities. Higher rates of monitoring were reported by those who reported receiving materials. Assessment of outcomes in a separate retrospective analysis of electronic medical record data showed lower levels of monitoring performed by specialist physicians. The monitoring activities observed were assessed as acceptable on the basis of the established performance of UK physicians, who are incentivized to deliver preventive screening.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26451964     DOI: 10.1097/YIC.0000000000000102

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  8 in total

1.  Quality of Reporting on the Evaluation of Risk Minimization Programs: A Systematic Review.

Authors:  Andrea M Russell; Elaine H Morrato; Rebecca M Lovett; Meredith Y Smith
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

2.  Evaluation of Physician Knowledge of the Key Safety Information for Aflibercept in Canada: Evaluation of Risk-Minimization Measures.

Authors:  Laurie J Zografos; Elizabeth Andrews; Dan L Wolin; Brian Calingaert; Eric K Davenport; Kelly A Hollis; Nada Djokanovic; Vito S Racanelli; Paul Petraro; Zdravko P Vassilev
Journal:  Pharmaceut Med       Date:  2019-06

3.  Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures.

Authors:  Laurie J Zografos; Elizabeth Andrews; Daniel L Wolin; Brian Calingaert; Eric K Davenport; Kelly A Hollis; Ursula Maria Schmidt-Ott; Paul Petraro; Zdravko P Vassilev
Journal:  Pharmaceut Med       Date:  2019-06

4.  Communication on Safety of Medicines in Europe: Current Practices and General Practitioners' Awareness and Preferences.

Authors:  Sieta T de Vries; Maartje J M van der Sar; Amelia Cupelli; Ilaria Baldelli; Anna Marie Coleman; Dolores Montero; Ivana Šipić; Adriana Andrić; Annika Wennberg; Jane Ahlqvist-Rastad; Petra Denig; Peter G M Mol
Journal:  Drug Saf       Date:  2017-08       Impact factor: 5.606

5.  Effectiveness of the golimumab educational program in ensuring healthcare professionals' awareness of risks described in the European risk management plan.

Authors:  Lauren Felo; Marijo Otero-Lobato; Anja Geldhof; Wim Noël
Journal:  Ther Adv Drug Saf       Date:  2019-05-15

6.  Pharmacists' perception of educational material to improve patient safety: A cross-sectional study on practices and awareness in Germany.

Authors:  André Said; Leonard Freudewald; Natalie Parrau; Matthias Ganso; Martin Schulz
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

7.  Evaluation of Risk-Minimization Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg: A Cross-Sectional Physician Survey.

Authors:  Kimberly H Davis; Alex Asiimwe; Laurie J Zografos; David J McSorley; Elizabeth B Andrews
Journal:  Pharmaceut Med       Date:  2017-08-28

8.  The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products.

Authors:  Meredith Y Smith; Andrea Russell; Priya Bahri; Peter G M Mol; Sarah Frise; Emily Freeman; Elaine H Morrato
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.